http://orcid.org/0000-0001-5015-2457
References
- Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(3):326–333.
- Stahl SM. Mechanism of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor. CNS Spectr. 2014;19(2):105–109.
- Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011;72(04):441–447.
- Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol. 2011;31(5):643–646.
- Pierz KA, Thase ME. A review of vilazodone, serotonin, and major depressive disorder. Prim Care Companion CNS Disord. 2014;16(1):pii: PCC.13r01554.
- Stork CM. 2019. Serotonin reuptake inhibitors and atypical antidepressants. In: Nelson LS, Howland MA, Lewin NA, et al., editors. Goldfrank’s toxicologic emergencies. New York (NY): McGraw-Hill.
- Gamble DE, Peterson LG. Trazodone overdose: four years of experience from voluntary reports. J Clin Psychiatry. 1986;47(11):544–546.
- Henry JA, Ali CJ, Caldwell R, et al. Acute trazodone poisoning: clinical signs and plasma concentrations. Psychopathology. 1984;17(2):77–81.
- Aan Het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009;180(3):305–313.
- Moher D, Liberati A, Tetzlaff J, PRISMA Group, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
- Acker EC, Sinclair EA, Beardsley AL, et al. Acute vilazodone toxicity in a pediatric patient. J Emerg Med. 2015;49(3):284–286.
- Carstairs SD, Griffith EA, Alayin T, et al. Recurrent seizure activity in a child after acute vilazodone ingestion. Ann Emerg Med. 2012;60(6):819.
- Del Pizzo J, Fernandez EK, Kopec KT, et al. Seizure after pediatric vilazodone ingestion: a case series. Ped Emerg Care. 2018;34(3):e51–e54.
- Fung BJ, Yanta JH, King AM, et al. Vilazodone may cause sodium channel blockade in overdose. J Med Toxicol. 2014;10:81.
- Pfeiffer S, Gunkelman S, Blackford M. Psychotropic exposures in pediatric patients: symptomatic iloperidone and vilazodone ingestions. Clin Toxicol. 2015;53(3):188.
- Rentmeester L, Saitman A, Chindarkar N, et al. Severe pediatric vilazodone toxicity with laboratory confirmation. Clin Toxicol. 2014;52:694.
- Gaw CE, Spiller HA, Russell JL, et al. Evaluation of dose and outcomes for pediatric vilazodone ingestions. Clin Toxicol. 2018;56(2):113–119.
- Russell JL, Spiller HA, Chounthirath T, et al. Pediatric ingestion of vilazodone compared to other selective serotonin reuptake inhibitor medications. Clin Toxicol. 201;55(5):352–356.
- Heise CW, Malashock H, Brooks DE. A review of vilazodone exposures with focus on serotonin syndrome effects. Clin Toxicol. 2017;55(9):1004–1007.
- Wolkin AF, Martin CA, Law RK, et al. Using poison center data for national public health surveillance for chemical and poison exposure and associated illness. Ann Emerg Med. 2012;59(1):56–61.
- Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–1120.
- American Association of Poison Control Centers. National Poison Data System (NPDS): NPDS Coding Users’ Manual, Version 3.1. 2014. https://aapcc.s3.amazonaws.com/pdfs/member-resources/NPDS_Coding_Users_Manual_v3.1_07May2014.pdf
- Trovis Pharmaceuticals. Prescribing info – Full Prescribing Information. [cited 2018 Dec 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022567s000lbl.pdf.
- Jaramillo JE, Marchbanks B, Willis B, et al. Evaluation of completeness of selected poison control center data fields. J Med Syst. 2010;34(4):499–507.